Skip Navigation LinksHome > September 2010 - Volume 25 - Issue 5 > Phosphodiesterase 4B genetic variants are not associated wit...
International Clinical Psychopharmacology:
doi: 10.1097/YIC.0b013e32833a5ff9
Original Articles

Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia

Souza, Renan P.a b c; Remington, Garya b; Meltzer, Herbert Y.d; Lieberman, Jeffrey A.e; Kennedy, James L.a b; Wong, Albert H.C.a c

Collapse Box

Abstract

Phosphodiesterase 4B (PDE4B) has been evaluated as a genetic risk factor for schizophrenia. Selective PDE4 inhibitor drugs have antipsychotic-like effects and reduce tardive dyskinesia-like movements in animal models. We investigated whether PDE4B genetic variants are associated with antipsychotic-induced tardive dyskinesia incidence and severity in schizophrenia patients. Our sample consisted of 169 Caucasian patients taking typical antipsychotic medication for at least 1 year. We found two PDE4B gene variants to be nominally associated with tardive dyskinesia (rs1338719 and rs7528545) in the overall population and two other variants nominally associated with the presence of tardive dyskinesia and severity in female patients (rs1890196 and rs783036). None of these results survived correction for multiple testing. Overall, our results do not support a genetic association between tardive dyskinesia and PDE4B.

© 2010 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.